Acarbose, an a-Glucosidase Inhibitor, Decreases Aortic Gene Expression and Serum Levels of Monocyte Chemoattractant Protein-1 in Fructose-fed Rats  

Oleh:

Nakamura, K. ; Yamagishi, S. ; Matsui, T. ; Yoshida, T.

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: The Journal of International Medical Research vol. 34 no. 05 (Sep. 2006), page 525-530.
Topik: Acarbose; antidiabetic agent; diabetes; insulin resistance; atherosclerosis; cardiovascular disease; post-prandial hyperglycaemia; monocyte chemoattractant protein-1 (MCP-1)

Ketersediaan

Perpustakaan FK Nomor Panggil: J11.K.05-06.01 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Insulin resistance is one of the determinants of post-prandial hyperglycaemia. Recently, acarbose, an á-glucosidase inhibitor that delays the absorption of carbohydrates from the small intestine, has been found to reduce the incidence of cardiovascular disease in patients with impaired glucose tolerance or diabetes. However, the molecular mechanism by which acarbose inhibits cardiovascular events remains unknown. In this study, we examined whether oral administration of acarbose could suppress expression of monocyte chemoattractant protein-1 (MCP-1) in fructose-fed rats, a widely used animal model of insulin resistance. Serum MCP-1 levels were elevated in fructose-fed rats after 4 weeks. Acarbose treatment for 4 weeks reduced the fructose-induced elevation of serum MCP-1 levels. Acarbose treatment for 8 weeks decreased MCP-1 mRNA levels in the aortae of fructose-fed rats. These results suggest that the cardioprotective effects of acarbose could be due, at least in part, to the suppression of MCP-1 expression.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali